Pulse Biosciences, Inc. PLSE
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -2.84% | 8.85% | 36.40% | 83.13% | 89.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.64% | 22.57% | 38.45% | 64.09% | 57.90% |
| Operating Income | -14.01% | -21.40% | -37.83% | -63.92% | -57.90% |
| Income Before Tax | -17.68% | -23.78% | -35.82% | -61.99% | -54.54% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.68% | -23.78% | -35.82% | -61.99% | -54.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.68% | -23.78% | -35.82% | -61.99% | -54.54% |
| EBIT | -14.01% | -21.40% | -37.83% | -63.92% | -57.90% |
| EBITDA | -14.39% | -21.99% | -38.83% | -65.73% | -59.59% |
| EPS Basic | -11.32% | -13.80% | -20.46% | -41.74% | -35.43% |
| Normalized Basic EPS | -10.36% | -12.76% | -21.47% | -42.85% | -36.60% |
| EPS Diluted | -11.32% | -13.80% | -20.46% | -41.74% | -35.43% |
| Normalized Diluted EPS | -10.36% | -12.76% | -21.47% | -42.85% | -36.60% |
| Average Basic Shares Outstanding | 5.76% | 9.30% | 13.54% | 14.50% | 13.83% |
| Average Diluted Shares Outstanding | 5.76% | 9.30% | 13.54% | 14.50% | 13.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |